{"title": "Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination", "author": "Alison M DeDent; Erica Farrand", "url": "https://thorax.bmj.com/content/77/1/9", "hostname": "thorax.bmj.com", "description": "After millions of deaths worldwide and months of widespread social and economic devastation, the first vaccine against SARS-CoV-2 (COVID-19) was given emergency use listing by the WHO.1 Approved only 1 year after the virus was first identified in Wuhan, China, this historic achievement was the result of public and private institutional partnerships, as well as decades of foundational scientific research. Two of the earliest vaccines authorised for widespread use were the BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) messenger RNA (mRNA) vaccines, demonstrating 95% and 94.1% efficacy, respectively, in phase II/III clinical trials. Notably, both vaccines have strong safety profiles, with the most common adverse events including injection site reactions, fever, chills, fatigue, headache, and muscle and joint aches.2 3 Postauthorisation reports of severe reactions, including anaphylaxis, have been extremely rare, occurring in only 4.5 reported cases per million doses.4 In this issue of Thorax , Park and colleagues5 present the first published case of COVID-19 vaccine-related interstitial lung disease (ILD). An 86-year-old man developed an acute onset of fever, weakness, shortness of breath and hypoxaemia requiring high-flow nasal cannula 1 day after receiving a dose of a COVID-19 mRNA vaccine. He had no history of ILD, connective tissue ...", "sitename": "Thorax", "date": "2022-01-01", "cleaned_text": "Article Text Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center's RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. After millions of deaths worldwide and months of widespread social and economic devastation, the first vaccine against SARS-CoV-2 (COVID-19) was given emergency use listing by the WHO.1 Approved only 1 year after the virus was first identified in Wuhan, China, this historic achievement was the result of public and private institutional partnerships, as well as decades of foundational scientific research. Two of the earliest vaccines authorised for widespread use were the BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) messenger RNA (mRNA) vaccines, demonstrating 95% and 94.1% efficacy, respectively, in phase II/III clinical trials. Notably, both vaccines have strong safety profiles, with the most common adverse events including injection site reactions, fever, chills, fatigue, headache, and muscle and joint aches.2 3 Postauthorisation reports of severe reactions, including anaphylaxis, have been extremely rare, occurring in only 4.5 reported cases per million doses.4 In this issue of Thorax, Park and colleagues5 present the first published case of COVID-19 vaccine-related interstitial lung disease (ILD). An 86-year-old man developed an acute onset of fever, weakness, shortness of breath and hypoxaemia requiring high-flow nasal cannula 1 day after receiving a dose of a COVID-19 mRNA vaccine. He had no history of ILD, connective tissue ... [View Full Text](https://thorax.bmj.com/content/77/1/9.full) Footnotes Twitter @ericafarrandMD Contributors AMD drafted the initial version of the manuscript, and AMD and EF participated in drafting all revisions. Both authors approved the final manuscript submitted for publication. Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Competing interests None declared. Provenance and peer review Commissioned; externally peer reviewed. Linked Articles Read the full text or download "}